Can I Take Reishi Mushroom with Repatha (Evolocumab)?

What Repatha Actually Does in the Body

Evolocumab is a fully human monoclonal IgG2 antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9) and blocks it from degrading LDL receptors on hepatocytes. With more functioning LDL receptors available, the liver clears more LDL-C from circulation.

Mechanism and Metabolism

Because evolocumab is a large-molecule biologic, it is not processed through cytochrome P450 enzymes, P-glycoprotein, or organic anion transporters. It is catabolized by general protein degradation pathways, the same routes the body uses for any IgG antibody. This means classic herb-drug pharmacokinetic interactions, the kind that dominate discussions about statins and St. John's wort, simply do not apply here.

Pharmacokinetic safety is only one dimension of safety.

Clinical Efficacy Data

The FOURIER trial (N=27,564) showed that adding evolocumab to statin therapy reduced LDL-C by 59% from a median baseline of 92 mg/dL, and reduced major adverse cardiovascular events (MACE) by 15% over a median follow-up of 2.2 years (P<0.001). [1] The GLAGUS and OSLER-1/2 extension data support durability of that LDL reduction across four years without tachyphylaxis or new safety signals directly tied to supplement co-use.

Repatha is approved by the FDA for adults with heterozygous or homozygous familial hypercholesterolemia and for those with established ASCVD who require additional LDL lowering beyond statin therapy. [2]

What Reishi Mushroom Does in the Body

Reishi (Ganoderma lucidum) is a wood-rotting basidiomycete used for over 2,000 years in East Asian medicine. Its pharmacologically active constituents include polysaccharides (particularly beta-glucans), triterpenes (ganoderic acids), and peptidoglycans.

Immune-Modulatory Activity

Reishi beta-glucans bind to Dectin-1 receptors and Toll-like receptor 2 on macrophages and dendritic cells, amplifying innate immune signaling. A 2006 randomized controlled trial (N=34) published in the Journal of Medicinal Food found that reishi extract at 1,800 mg/day for 12 weeks significantly elevated natural killer cell activity and CD4/CD8 ratios in healthy adults. [3] This immune stimulation is generally considered beneficial in cancer-support contexts, but it raises a specific question for Repatha users: evolocumab is itself a biologically derived protein, and immune activation could theoretically alter anti-drug antibody formation, though this remains a theoretical rather than documented risk at standard reishi doses.

Antiplatelet and Anticoagulant Activity

This is the more clinically concrete concern. Triterpene compounds in reishi, particularly ganoderic acid B and ganodereic acid C, inhibit thromboxane B2 synthesis and reduce ADP-induced platelet aggregation. A 1988 study in Chemical and Pharmaceutical Bulletin (Tao and Feng) documented platelet aggregation inhibition in vitro, and a later human study confirmed reduced platelet aggregation with 1.5 g/day of reishi extract over four weeks. [4]

Patients on Repatha are typically also on antiplatelet therapy (aspirin, clopidogrel) or anticoagulants. Adding reishi to that regimen may produce additive antiplatelet effects.

Lipid-Lowering Effects of Reishi

A 2016 meta-analysis published in PLOS ONE (N=5 RCTs, 398 participants) found that Ganoderma lucidum supplementation produced a statistically non-significant trend toward reduced total cholesterol and LDL-C compared with placebo, with no consistent effect size across doses. [5] The effect is modest at best. For a patient already achieving 50-to-60% LDL reduction on evolocumab, reishi's lipid activity is unlikely to meaningfully add to or subtract from therapeutic effect, but it has not been tested in combination.

Is There a Direct Drug-Supplement Interaction?

No published human study has examined the direct combination of evolocumab and Ganoderma lucidum. Because the interaction data are indirect, the risk assessment must be built from mechanistic reasoning and class-level evidence.

Pharmacokinetic Interaction: Low Probability

Evolocumab's catabolism is entirely independent of hepatic CYP450 enzymes. Reishi's known enzyme effects include mild CYP3A4 and CYP2E1 inhibition in rodent models [6], but monoclonal antibodies are not substrates for these enzymes. A pharmacokinetic interaction is unlikely to be clinically relevant.

Pharmacodynamic Interaction: Real but Manageable

The pharmacodynamic concern has two components.

First, additive antiplatelet effects are real. PCSK9 inhibitor therapy is typically prescribed to patients with established ASCVD, who are already on aspirin and often a P2Y12 inhibitor. Adding a supplement with antiplatelet activity to dual antiplatelet therapy creates a triple-antiplatelet situation. No dose-specific threshold for reishi-induced bleeding has been established in clinical trials.

Second, immune modulation from reishi could theoretically influence the immunogenic profile of a biologic drug, though anti-evolocumab antibody formation is already very low. In the FOURIER trial, binding antibody incidence was 0.3% and neutralizing antibody incidence was 0% at 48 weeks. [1] Any reishi-related amplification of that signal would likely be clinically undetectable.

The HealthRX three-tier pharmacodynamic risk framework rates the reishi-evolocumab combination as Tier 2 (Monitor): no contraindication, no required dose separation window, but clinician disclosure is warranted and platelet function monitoring is appropriate for high-dose or long-duration reishi use (greater than 1 g/day for more than 8 weeks).

Who Is at Greatest Risk from This Combination?

Not every Repatha patient faces the same level of concern. The risk profile is higher in specific subgroups.

Patients on Antiplatelet or Anticoagulant Therapy

Dual antiplatelet therapy (aspirin plus clopidogrel or ticagrelor) is standard for patients with recent ACS or stent placement. Adding reishi to this regimen could increase bleeding risk in ways that are difficult to monitor without specific platelet function testing. The ACC/AHA 2019 primary prevention guidelines note that bleeding risk should always be weighed against cardiovascular benefit when adding agents with antiplatelet properties. [7]

Patients with Hepatic Disease

High-dose reishi (above 2 g/day of concentrated extract) has been linked to hepatotoxicity in case reports. A 2004 report in the Annals of Internal Medicine described a patient who developed acute hepatitis after consuming powdered reishi at 2 g twice daily. [8] Evolocumab itself is not hepatotoxic, but any supplement-related liver injury would compromise overall cardiovascular care and potentially alter drug metabolism for co-administered statins.

Post-Surgical or Peri-Procedural Patients

Patients preparing for CABG, PCI, or any surgical procedure should discontinue reishi at least 7 to 14 days before the procedure, given its antiplatelet activity. This mirrors guidance given for fish oil, vitamin E, and garlic supplements.

Does Reishi Mushroom Affect Cholesterol Independently?

Some patients use reishi specifically hoping it will lower LDL. The evidence does not support replacing or meaningfully supplementing Repatha with reishi for this purpose.

What the Meta-Analysis Shows

The 2016 PLOS ONE meta-analysis referenced above tested reishi against placebo in adults with various lipid levels at doses ranging from 1.44 g to 5.4 g per day over 12 to 16 weeks. [5] Total cholesterol reductions ranged from 3 to 6 mg/dL, and LDL-C changes were inconsistent across trials. Compare that to evolocumab's median LDL reduction of 56 mg/dL in the FOURIER trial. Reishi is not a substitute for PCSK9 inhibition.

Possible Mechanism for Modest Lipid Effects

Reishi ganoderic acids inhibit HMG-CoA reductase activity in animal models, the same enzyme targeted by statins. The inhibition is substantially weaker than statin-level blockade. Any additive effect when combined with a PCSK9 inhibitor is speculative because the combination has not been studied in a human trial.

Practical Guidance: Taking Reishi While on Repatha

The following guidance applies to adults prescribed evolocumab 140 mg every 2 weeks or 420 mg monthly who are considering or currently using reishi mushroom in any form.

Tell Your Prescriber Before Starting

Disclose reishi use at your next cardiology or primary care visit. This matters most if you are also on aspirin, clopidogrel, ticagrelor, warfarin, rivaroxaban, apixaban, or any other antiplatelet or anticoagulant agent. Your clinician should know the dose and form of reishi you are taking (whole mushroom powder, hot-water extract, alcohol extract, or spore oil).

Dosing Considerations

Doses below 1 g/day of standardized reishi extract carry a lower bleeding-risk profile based on available data. Doses above 2 g/day of concentrated extract are where hepatotoxicity case reports cluster. Standard over-the-counter reishi supplements in the United States typically provide 500 mg to 1,000 mg per capsule.

No dose-separation window between reishi and the Repatha injection is required because no pharmacokinetic mechanism has been identified. Repatha is injected subcutaneously every 2 weeks or monthly; the timing of reishi consumption relative to injection day is not pharmacologically meaningful.

Monitoring Parameters

If you continue reishi alongside Repatha, reasonable monitoring includes:

• Platelet function or CBC at 3 to 6 months if using reishi at doses above 1 g/day, especially with concurrent antiplatelet therapy.
• Liver function tests (AST, ALT) at 3 months if using high-dose reishi (above 1.5 g/day) or if you have pre-existing hepatic conditions.
• Report promptly any unusual bruising, prolonged bleeding from small cuts, blood in urine or stool, or unexpected fatigue.

Your LDL-C should continue to be monitored at the intervals recommended by your cardiologist, typically 4 to 12 weeks after starting or changing therapy per the ACC/AHA 2018 Blood Cholesterol Guideline. [9]

What Current Guidelines Say (and Don't Say)

The ACC/AHA 2018 Blood Cholesterol guideline and its 2022 focused update do not address herbal or mushroom supplements in the context of PCSK9 inhibitor therapy. This gap is common across major cardiovascular guidelines; the evidence base for specific supplement-drug combinations in this drug class simply does not yet exist at trial scale.

The American Heart Association's 2023 scientific statement on dietary supplements and cardiovascular disease states: "Clinicians should routinely ask about supplement use because patients often do not volunteer this information, and some supplements carry pharmacodynamic interactions with standard cardiovascular medications that are clinically relevant." [10] That guidance applies directly here.

The Natural Medicines Comprehensive Database rates the Ganoderma lucidum plus anticoagulant/antiplatelet combination as a "Moderate" interaction requiring clinical monitoring, though its PCSK9-inhibitor-specific entry does not yet exist as of the article's review date.

Frequently Asked Questions